156 related articles for article (PubMed ID: 28662136)
21. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice.
Yang L; Miura K; Zhang B; Matsushita H; Yang YM; Liang S; Song J; Roh YS; Seki E
Cell Mol Gastroenterol Hepatol; 2017 May; 3(3):469-483. PubMed ID: 28462384
[TBL] [Abstract][Full Text] [Related]
22. Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats.
Arima S; Uto H; Ibusuki R; Kumamoto R; Tanoue S; Mawatari S; Oda K; Numata M; Fujita H; Oketani M; Ido A; Tsubouchi H
Int J Mol Med; 2014 Jan; 33(1):68-76. PubMed ID: 24190226
[TBL] [Abstract][Full Text] [Related]
23. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
Okishio S; Yamaguchi K; Ishiba H; Tochiki N; Yano K; Takahashi A; Kataoka S; Okuda K; Seko Y; Liu Y; Fujii H; Takahashi D; Ito Y; Kamon J; Umemura A; Moriguchi M; Yasui K; Okanoue T; Itoh Y
Sci Rep; 2020 Nov; 10(1):19578. PubMed ID: 33177546
[TBL] [Abstract][Full Text] [Related]
24. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice.
Kodama Y; Kisseleva T; Iwaisako K; Miura K; Taura K; De Minicis S; Osterreicher CH; Schnabl B; Seki E; Brenner DA
Gastroenterology; 2009 Oct; 137(4):1467-1477.e5. PubMed ID: 19549522
[TBL] [Abstract][Full Text] [Related]
25. Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy.
Xavier A; Zacconi F; Santana-Romo F; Eykyn TR; Lavin B; Phinikaridou A; Botnar R; Uribe S; Oyarzún JE; Cabrera D; Arrese M; Andia ME
Ann Hepatol; 2021; 25():100358. PubMed ID: 33962045
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis.
Chen H; Zhao W; Yan X; Huang T; Yang A
J Clin Transl Hepatol; 2022 Aug; 10(4):577-588. PubMed ID: 36062292
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
28. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.
Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP
Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211
[TBL] [Abstract][Full Text] [Related]
29. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet.
Uto H; Nakanishi C; Ido A; Hasuike S; Kusumoto K; Abe H; Numata M; Nagata K; Hayashi K; Tsubouchi H
Hepatol Res; 2005 Aug; 32(4):235-42. PubMed ID: 16085455
[TBL] [Abstract][Full Text] [Related]
30. Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats.
Karahan N; Işler M; Koyu A; Karahan AG; Başyığıt Kiliç G; Cırış IM; Sütçü R; Onaran I; Cam H; Keskın M
Turk J Gastroenterol; 2012 Apr; 23(2):110-21. PubMed ID: 22706738
[TBL] [Abstract][Full Text] [Related]
31. Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.
Nishi T; Yamamoto Y; Yamagishi N; Iguchi M; Tamai H; Ito T; Tsuruo Y; Ichinose M; Kitano M; Ueyama T
J Pharm Pharmacol; 2018 Mar; 70(3):383-392. PubMed ID: 29355950
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of hepatocarcinogenesis initiated with diethylnitrosamine or N-nitrosobis(2-hydroxypropyl)amine by a choline-deficient, L-amino acid-defined diet administered prior to the carcinogen exposure in rats.
Kishida H; Nakae D; Kobayashi Y; Kusuoka O; Kitayama W; Denda A; Fukui H; Konishi Y
Exp Toxicol Pathol; 2000 Oct; 52(5):405-12. PubMed ID: 11089891
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.
Yang L; Roh YS; Song J; Zhang B; Liu C; Loomba R; Seki E
Hepatology; 2014 Feb; 59(2):483-95. PubMed ID: 23996730
[TBL] [Abstract][Full Text] [Related]
34. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
Afonso MB; Rodrigues PM; Mateus-Pinheiro M; Simão AL; Gaspar MM; Majdi A; Arretxe E; Alonso C; Santos-Laso A; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Banales JM; Ratziu V; Gautheron J; Castro RE; Rodrigues CMP
Gut; 2021 Dec; 70(12):2359-2372. PubMed ID: 33361348
[TBL] [Abstract][Full Text] [Related]
35. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
Enomoto M; Kaji K; Nishimura N; Fujimoto Y; Murata K; Takeda S; Tsuji Y; Fujinaga Y; Takaya H; Kawaratani H; Namisaki T; Akahane T; Yoshiji H
Dig Liver Dis; 2022 Oct; 54(10):1392-1402. PubMed ID: 35514019
[TBL] [Abstract][Full Text] [Related]
36. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice.
Wang B; Majumder S; Nuovo G; Kutay H; Volinia S; Patel T; Schmittgen TD; Croce C; Ghoshal K; Jacob ST
Hepatology; 2009 Oct; 50(4):1152-61. PubMed ID: 19711427
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
[TBL] [Abstract][Full Text] [Related]
38. Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis.
Yang YM; Fukui M; Wang Z; Miao F; Karriker MJ; Seki E
Front Endocrinol (Lausanne); 2018; 9():378. PubMed ID: 30083132
[No Abstract] [Full Text] [Related]
39. Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
Ishizu-Higashi S; Seno H; Nishi E; Matsumoto Y; Ikuta K; Tsuda M; Kimura Y; Takada Y; Kimura Y; Nakanishi Y; Kanda K; Komekado H; Chiba T
PLoS One; 2014; 9(5):e98017. PubMed ID: 24849253
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte glutathione peroxidase-1 deficiency improves hepatic glucose metabolism and decreases steatohepatitis in mice.
Merry TL; Tran M; Dodd GT; Mangiafico SP; Wiede F; Kaur S; McLean CL; Andrikopoulos S; Tiganis T
Diabetologia; 2016 Dec; 59(12):2632-2644. PubMed ID: 27628106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
